EA201491047A1 - Лечение когнитивных нарушений при синдроме хантера путем интратекальной доставки идуронат-2-сульфатазы - Google Patents
Лечение когнитивных нарушений при синдроме хантера путем интратекальной доставки идуронат-2-сульфатазыInfo
- Publication number
- EA201491047A1 EA201491047A1 EA201491047A EA201491047A EA201491047A1 EA 201491047 A1 EA201491047 A1 EA 201491047A1 EA 201491047 A EA201491047 A EA 201491047A EA 201491047 A EA201491047 A EA 201491047A EA 201491047 A1 EA201491047 A1 EA 201491047A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment
- sulfatase
- syndrome
- iuronat
- hanter
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Настоящее изобретение обеспечивает способ лечения когнитивных нарушений при синдроме Хантера. В числе прочего, настоящее изобретение обеспечивает способ, включающий этап интратекального введения субъекту, нуждающемуся в лечении, рекомбинантного фермента идуронат-2-сульфатазы (I2S) в терапевтически эффективной дозе и с интервалом введения в течение периода лечения, достаточным для улучшения, стабилизации или ослабления снижения одной или более из когнитивных, адаптивных, моторных и/или управляющих функций по сравнению с контролем.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261734365P | 2012-12-06 | 2012-12-06 | |
PCT/US2012/071495 WO2013096912A2 (en) | 2011-12-23 | 2012-12-21 | Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201491047A1 true EA201491047A1 (ru) | 2015-02-27 |
EA039246B1 EA039246B1 (ru) | 2021-12-22 |
Family
ID=80632884
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201491047A EA039246B1 (ru) | 2012-12-06 | 2012-12-21 | Способ лечения когнитивных нарушений, связанных с синдромом хантера |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA039246B1 (ru) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004055157A2 (en) * | 2002-08-13 | 2004-07-01 | Whitley Chester B | Methods of using vectors to treat metabolic disorders |
AR059089A1 (es) * | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
US7722865B2 (en) * | 2008-01-18 | 2010-05-25 | Biomarin Pharmaceutical Inc. | Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof |
KR20230159646A (ko) * | 2010-06-25 | 2023-11-21 | 샤이어 휴먼 지네틱 테라피즈 인크. | 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들 |
-
2012
- 2012-12-21 EA EA201491047A patent/EA039246B1/ru unknown
Also Published As
Publication number | Publication date |
---|---|
EA039246B1 (ru) | 2021-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201590880A1 (ru) | Композиции и способы лечения протеинопатий | |
EA201491773A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата | |
PH12018501903A1 (en) | Methods of treating depression using orexin-2 receptor antagonists | |
MX2017012426A (es) | Composiciones y metodos para modular la expresion de tmprss6. | |
MX2016002645A (es) | Tratamiento combinado para tratar el glioblastoma. | |
EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
WO2011020061A3 (en) | Compositions and methods of for treating bipolar disorder | |
WO2012093258A3 (en) | Irf5- related treatment and screening | |
MX2014011836A (es) | Administracion subcutanea de iduronato-2-sulfatasa. | |
MX2015012156A (es) | Terapia de induccion de rituximab seguida por terapia de acetato de glatiramer. | |
MX2020000083A (es) | Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand. | |
MX2019007779A (es) | Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe). | |
MX360189B (es) | Terapia de combinacion para el tratamiento de glioblastoma. | |
MX2019001633A (es) | Proteina derivada de la seda para el tratamiento de la inflamacion. | |
EA201991650A1 (ru) | Способы лечения неврологических расстройств | |
MX2020011190A (es) | Angiotensina ii sola o en combinacion para usarse en el tratamiento de hipotension. | |
WO2015067755A3 (en) | Novel methods and antibodies for treating coagulapathy | |
EA201792099A1 (ru) | Лечение когнитивных нарушений при синдроме хантера путем интратекальной доставки идуронат-2-сульфатазы | |
MX366134B (es) | Angiotensina en el tratamiento de condiciones cerebrales. | |
EA201591424A1 (ru) | Способы лечения дефицита железа растворимым пирофосфатом железа | |
WO2019157495A3 (en) | Methods for preventing and/or treating bone loss conditions by modulating irisin | |
MX2015011775A (es) | Uso de levocetirizina y montelukast en el tratamiento de anafilaxis. | |
MX2015016143A (es) | Peptidos de angiotensina para tratar el sindrome de marfan y transtornos relacionados. | |
EA201491047A1 (ru) | Лечение когнитивных нарушений при синдроме хантера путем интратекальной доставки идуронат-2-сульфатазы | |
PH12018550102A1 (en) | Methods and compositions for treating hunter syndrome |